Provectus Biopharmaceuticals Inc Revenue Growth Rates (PVCT), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Provectus Biopharmaceuticals Inc   (PVCT)
 

PVCT's Revenue Growth by Quarter and Year

Provectus Biopharmaceuticals Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/PVCT/growth
https://api.csimarket.com/api/v1/companies/PVCT/fundamentals
https://api.csimarket.com/api/v1/companies/PVCT/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
PVCT Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 0.00
2nd Quarter June 0.00
1st Quarter March 0.00
FY 0.00





PVCT Revenue third quarter 2026 Y/Y Growth Comment
Provectus Biopharmaceuticals Inc in the third quarter 2026 recorded of $ 0.00 millions.

Looking into third quarter 2026 results within Major Pharmaceutical Preparations industry 155 other companies have achieved higher Revenue growth. While Provectus Biopharmaceuticals Inc ' s Revenue no change of 0% ranks overall at the positon no. 3459 in the third quarter 2026.


PVCT Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June -
1st Quarter March -
FY   -

Financial Statements
Provectus Biopharmaceuticals Inc 's third quarter 2026 Revenue $ 0.00 millions PVCT's Income Statement
Provectus Biopharmaceuticals Inc 's third quarter 2025 Revenue $ 0.00 millions Quarterly PVCT's Income Statement


PVCT Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June -
1st Quarter March -
FY (Year on Year)   -


Back to PVCT Growth rate Comparisons >> Back to PVCT Growth rate Comparisons >>


Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #156
Healthcare Sector #472
Overall #3459

Revenue Y/Y Growth Statistics
High Average Low
20.36 % -13.5 % -43.61 %
(Sep 30 2024)   (Dec 31 2023)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #156
Healthcare Sector #472
Overall #3459
Revenue Y/Y Growth Statistics
High Average Low
20.36 % -13.5 % -43.61 %
(Sep 30 2024)   (Dec 31 2023)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Provectus Biopharmaceuticals Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


PVCT's III. Quarter Q/Q Revenue Comment


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


PVCT's III. Quarter Q/Q Revenue Comment


Provectus Biopharmaceuticals Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2026)		 12 Months Ending (Jun 30 2026) 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025)
Cumulative Revenue 12 Months Ending $ 0.00
Y / Y Revenue Growth (TTM) -
Year on Year Revenue Growth Overall Ranking # 3479
Seqeuential Revenue Change (TTM) -
Seq. Revenue Growth (TTM) Overall Ranking # 3459


Cumulative Revenue growth Comment
In the Sep 30 2026 period, Provectus Biopharmaceuticals Inc 's cumulative trailing twelve month Revenue remained unchanged compare to the same period a year ago.

In the Healthcare sector 473 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 980 to 3479.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 156
Healthcare Sector # 474
Overall # 3479

Revenue TTM Y/Y Growth Statistics
High Average Low
20.36 %
 -13.5 %
-43.61 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 156
Sector # 472
S&P 500 # 3459
Cumulative Revenue growth Comment
In the Sep 30 2026 period, Provectus Biopharmaceuticals Inc 's cumulative trailing twelve month Revenue remained unchanged compare to the same period a year ago.

In the Healthcare sector 473 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 980 to 3479.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 156
Healthcare Sector # 474
Overall # 3479

Revenue TTM Y/Y Growth Statistics
High Average Low
20.36 %
-13.5 %
-43.61 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 156
Sector # 472
S&P 500 # 3459




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
PVCT's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue no change for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Viatris Inc -0.28%$ -0.277 millions
Zoetis Inc -0.38%$ -0.375 millions
Pfizer Inc-0.43%$ -0.426 millions
Standard Biotools Inc -0.51%$ -0.508 millions
Lucid Diagnostics Inc -0.66%$ -0.661 millions
Globus Medical Inc -0.69%$ -0.693 millions
Conmed Corporation-0.70%$ -0.701 millions
Surgery Partners Inc -0.75%$ -0.755 millions
Myriad Genetics Inc -1.03%$ -1.025 millions
Lensar Inc -1.29%$ -1.292 millions
Fortrea Holdings Inc -1.40%$ -1.397 millions
Immunocore Holdings Plc-1.42%$ -1.419 millions
Pacira Biosciences inc -1.59%$ -1.595 millions
Organon and Co -1.75%$ -1.748 millions
Teva Pharmaceutical Industries Limited-1.90%$ -1.897 millions
Skinhealth Systems Inc -2.07%$ -2.071 millions
Charles River Laboratories International inc -2.20%$ -2.201 millions
Inogen Inc -2.40%$ -2.399 millions
Novavax inc -3.05%$ -3.048 millions
Seer Inc -3.14%$ -3.139 millions
Teladoc Health Inc -3.41%$ -3.406 millions
Scientific Industries Inc -3.50%$ -3.504 millions
Cg Oncology Inc -3.72%$ -3.721 millions
Treace Medical Concepts Inc -3.91%$ -3.905 millions
Sarepta Therapeutics Inc -4.51%$ -4.509 millions
Pacific Health Care Organization Inc-4.69%$ -4.689 millions
Tela Bio Inc -5.06%$ -5.058 millions
Perrigo Company Plc-5.22%$ -5.225 millions
Heron Therapeutics Inc -5.49%$ -5.493 millions
Milestone Scientific Inc -5.95%$ -5.948 millions


About Provectus Biopharmaceuticals Inc Revenue Growth Rates (PVCT), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Provectus Biopharmaceuticals Inc (CIK 315545).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001493152-26-050944
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Provectus Biopharmaceuticals Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.